NEW YORK — Kyowa Hakko Bio Co., Ltd., a subsidiary of Kirin Holdings Co., Ltd., Tokyo, launched Immuse, a novel dietary supplement ingredient, in the United States.

Immuse is a patented Lactococcus lactis strain plasma discovered by the fermentation technology company. The paraprobiotic ingredient activates cells such as NK, Killer-T, Helper-T, and B cells to provide broad-range immune support, Kyowa Hakko said.

It is stable for use in a variety of applications, including tablets, capsules and gummy formulations, and already is on the market as a finished product in Japan, where it is sold in the form of functional beverages, yogurt, tablets and gummies.